DrugPatentWatch Database Preview

Drugs in Development Information for Tamibarotene

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Tamibarotene?

Tamibarotene is an investigational drug.

There have been 9 clinical trials for Tamibarotene. The most recent clinical trial was a Phase 2 trial, which was initiated on February 8^th 2021.

The most common disease conditions in clinical trials are Leukemia, Syndrome, and Preleukemia. The leading clinical trial sponsors are CytRx, Syros Pharmaceuticals, and Osaka City University.

There are four hundred and twenty-eight US patents protecting this investigational drug and three international patents.

Summary for Tamibarotene

US Patents	428
International Patents	3,581
US Patent Applications	1,406
WIPO Patent Applications	699
Japanese Patent Applications	347
Clinical Trial Progress	Phase 2 (2021-02-08)
Vendors	87

Recent Clinical Trials for Tamibarotene

Title	Sponsor	Phase
SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Syros Pharmaceuticals	Phase 3
A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Syros Pharmaceuticals	Phase 2
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer	CytRx	Phase 2

See all Tamibarotene clinical trials

Clinical Trial Summary for Tamibarotene

Top disease conditions for Tamibarotene

Top clinical trial sponsors for Tamibarotene

See all Tamibarotene clinical trials

US Patents for Tamibarotene

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Tamibarotene		Anticancer agent	Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)
Tamibarotene		Pyrrolidinone derivatives as MetAP-2 inhibitors	Merck Patent GmbH (Darmstadt, DE)
Tamibarotene		.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof	Quadriga Biosciences, Inc. (Los Altos, CA)
Tamibarotene		Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)	BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)
Tamibarotene		Aryl-cyanoguanidine compounds	Bayer Pharma Aktiengesellschaft (Berlin, DE)
Tamibarotene		Heteroaryl compounds as IRAK inhibitors and uses thereof	Merck Patent GmbH (Darmstadt, DE)

International Patents for Tamibarotene

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Tamibarotene	Australia	AU2015272560	2034-06-09
Tamibarotene	Canada	CA2951627	2034-06-09
Tamibarotene	Denmark	DK3153508	2034-06-09
Tamibarotene	European Patent Office	EP3153508	2034-06-09
Tamibarotene	Japan	JP2019206529	2034-06-09
Tamibarotene	Japan	JP6549115	2034-06-09